The initial clinical trial on ‘PNEUMOSTEM^®’ which is the stem cell lung disease medicine under development by MEDIPOST in U.S., was successfully administrated to a subject patient as the 1st and 2nd clinical trial.

‘PNEUMOSTEM^®’ which is the preventive medicine for Broncho pulmonary Dysplasia under development by MEDIPOST, was designated as Orphan Drug by European Medicines Agency.

Based on the designation as Orphan Drug this time, MEDIPOST acquired the exclusive sales right of Broncho pulmonary Dysplasia medicine for 12 years after permit in the whole 28 EU member countries.

Broncho pulmonary Dysplasia is the disease which is the main cause of death by premature babies and complications. ‘PNEUMOSTEM^®’ uses mesenchyma stem cell extracted from cord blood as the material.

‘PNEUMOSTEM^®’ was designated as Orphan Drug this time, as existing medicines are scarce in Broncho pulmonary Dysplasia area and as the EMA highly assessed the chance of success as new medicine on for ‘PNEUMOSTEM^®’.

The result of designation as Orphan Drug this time was posted on the official website of European Commission.